Exploring the effectiveness of low continuous chemo-bio-therapeutic treatment of cancer through analytical system modelling

Journal of Biological Systems

Volumn 14, Issue 1, 2006, Pages 1-12

  Mukherjee, Abhik ^a   Majumder, Durjoy ^b   Icbal, Asif ^c  

^a INDIAN INSTITUTE OF ENGINEERING SCIENCE AND TECHNOLOGY   (India)

^b Durgapur Institute of Advanced Technology and Management ^*  (India)

^c Durgapur Institute of Advanced Technology and Management   (India)

Author keywords

Angiogenesis; Immunity; Metronomic Chemotherapy; Physiological State; Tumor Dynamics

Indexed keywords

EID: 33344478361     PISSN: 02183390     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0218339006001696     Document Type: Article

References (18)

1. Tao Y, Yoshida, N, Guo Q, Nonlinear analysis of a model of vascular tumor and treatment, Nonlinearity 17:867-895, 2004.
2. Repetto L, Greater risks of chemotherapy toxicity in elderly patients with cancer, J Support Oncol 1:18-24, 2003.
3. Kaur H, Budd T, Metronomic therapy for breast cancer, Curr Oncol Rept 6:49-52, 2004.
4. Hahnfeldt P, Folkman J, Hlatky L, Minimizing long term tumor burden: the logic for metronomic chemotherapeutic dosing and its anti-angiogenic basis, J Theor Biol 220:545-554, 2003.
5. Kerbel RS, Kamen BA, The anti-angiogenic basis of metronomic chemotherapy, Nat Rev Cancer 4:423-436, 2004.
6. Stoll BR, Migliorini C, Kadambi A, Munn L, Jain RK, A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy, Blood 102:2555-2561, 2003.
7. Kaplan D, Glass L, One-dimensional differential equations, in Understanding Nonlinear Dynamics, Springer-Verlag, New York-Berlin-London, pp. 147-207, 1995.
8. Filipovich AH, Spector BD, Kersey J, Immunodeficiency in humans as a risk factor in development of malignancy, Prev Med 9:252-259, 1980.
9. Mathe G, Reizenstein P, Pathophysiological Aspects of Cancer Immunology, Pergamon Press, Oxford, UK, 1985.
10. Robert S, Optimal Control and Estimation, Dover Publications, 1994.
11. Ogata K, Modern Control Engineering, Prentice Hall, 1990.
12. Ben-Efraim S, Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity, Curr Drug Targets 2:197-212, 2001.
13. Hilborn RC, Chaos and Nonlinear Dynamics, Oxford University Press, 2000.
14. MATLAB user's guide, The Mathworks Inc.
15. Piccart-Gebhart MJ, Mathematics and oncology: a match for life?, J Clin Oncol 21:1425-1428, 2003.
16. Tulpule A, Groopman J, Saville MW, Harrington W Jr, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS, Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma, Cancer 95:147-154, 2002.
17. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity, J Clin Invest 105:R15-24, 2000.
18. Kerbel R, Folkman J, Clinical translation of angiogenesis inhibitors, Nat Rev Cancer 2:727-739, 2002.